Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25652151 | 0.86 | NOS3 (0.37) | UHRF1NOS3NOS1NOS2ALDH1A1 | |
| SCHEMBL21558448 | 0.78 | SIRT3 (0.36) | NOS1ALDH1A1CYP3A4SMN1; SMN2TDP1 | |
| SCHEMBL25652161 | 0.70 | UHRF1 (0.42) | UHRF1NOS3NOS1NOS2ALDH1A1 | |
| SCHEMBL25652419 | 0.69 | UHRF1 (0.37) | UHRF1NOS3NOS1NOS2 | |
| SCHEMBL25652156 | 0.69 | NOS2 (0.40) | NOS3NOS2 | |
| SCHEMBL21558451 | 0.68 | CYP2D6 (0.36) | ALDH1A1CYP3A4SMN1; SMN2 | |
| SCHEMBL317221 | 0.66 | UHRF1 (0.52) | UHRF1NOS3NOS1NOS2ALDH1A1 | |
| SCHEMBL18868429 | 0.66 | CYP3A4 (0.44) | ALDH1A1CYP3A4TDP1 | |
| SCHEMBL29707486 | 0.66 | UHRF1 (0.52) | UHRF1NOS3NOS1NOS2ALDH1A1 | |
| SCHEMBL21558728 | 0.66 | CYP2E1 (0.39) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183221-A1 | PYRIDINE DERIVATIVE AND APPLICATION THEREOF | NICOYA THERAPEUTICS (SHANGHAI) CO., LTD (CN) | 2023-06-15 | — | — | US | disclosed |
| US-20230183221-A1 | PYRIDINE DERIVATIVE AND APPLICATION THEREOF | NICOYA THERAPEUTICS (SHANGHAI) CO., LTD (CN) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183221-A1 | PYRIDINE DERIVATIVE AND APPLICATION THEREOF | XDH, CYP11B2, DPYD | UHRF1 4700/4885NOS3 1523/4885NOS1 1826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.